Recombinant Human KRAS G12V (HLA-A*03:01)(His-Avi Tag)

Scan for product

HEK293表达系统癌症研究药物筛选免疫学研究

Product no.93001ES Sizes1 options SourceYeasen · Official

Cat. No. 93001ES20 现货 ¥1,195.00

Qty 1

Enquire now

Enquire / bulk Compare

Specifications & Enquiry

Tick the specs you need to submit them together; or enquire one by one. Cat. numbers are carried into the RFQ.

Cat.No Spec Price Status

93001ES20 20 μg ¥1,195.00 现货 Enquire

Submit enquiry Price is on application; bulk sizes can be sampled on request.

Overview

Specifications

Brand翌圣生物 Yeasen

Cat.No93001ES

Specification高纯度、高活性、低内毒素、高批间一致性

Origin翌圣生物科技(上海)股份有限公司

技术平台 HEK293表达系统

应用方法 癌症研究研究KRAS突变相关肿瘤发生发展机制 药物筛选筛选KRAS抑制剂及合成致死相互作用子 免疫学研究研究MHC-多肽复合物与T细胞受体等相互作用

适用物种种属人

检测方法 SDS-PAGE HPLC LAL SPR Tris-Bis PAGE

生物特性参数 蛋白类型MHC多肽复合物 种属来源人 生物活性描述Human KRAS G12V (HLA-A*03:01) Complex His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-KRAS G12V (HLA-A*03:01) Antibody with an affinity constant of 0.205μM as determined in SPR assay (Biacore T200). 应用癌症研究、药物筛选

样本类型 重组蛋白

技术参数纯度> 95% as determined by SDS-PAGE and HPLC 内毒素水平< 1.0 EU per μg by the LAL method 分子量Approximately 50.2 kDa. Due to glycosylation the protein migrates to 55-60 kDa based on Tris-Bis PAGE result. 制剂形式Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization. 活性Binds Anti-KRAS G12V (HLA-A*03:01) Antibody with an affinity constant of 0.205μM as determined in SPR assay (Biacore T200). 储存条件-25 ~ -15℃保存，收到货之后有效期1年。复溶后，无菌条件下，-85 ~ -65℃保存，3个月有效期。 表达系统HEK293 标签C-His-Avi 表达序列Gly25-Thr305(HLA-A*03:01) Ile21-Met119(B2M) and VVVGAVGVGK peptide 登录号NP_002107.3 (HLA-A*03:01) & P61769 (B2M) & VVGAVGVGK 外观Lyophilized Powder 复溶方法开盖之前，先离心。使用蒸馏水复溶冻干的蛋白质，复溶浓度超过100 μg/mL。建议首次使用时将蛋白分装为每次实验用量，避免反复冻融。 复溶浓度> 100 μg/mL 质量标准高纯度、高活性、低内毒素、高批间一致性